Morepen Laboratories Ltd Quarterly Results
Q3 FY25-26 Results Summary
Revenue
The revenue stands at ₹484.16 crore, reflecting a quarter-on-quarter *(QoQ) increase of 17.63 per cent from ₹411.58 crore. This corresponds to a year-on-year *(YoY) growth of 6.93 per cent.
Operating Profit
Operating Profit stands at ₹33.25 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 38.54 per cent from ₹54.10 crore. This corresponds to a year-on-year *(YoY) growth of 2.85 per cent.
PBDT
PBDT stands at ₹18.31 crore, reflecting a quarter-on-quarter *(QoQ) increase of 14.94 per cent from ₹15.93 crore. This corresponds to a year-on-year *(YoY) growth of 36.13 per cent.
Profit Before Tax
Profit Before Tax stands at ₹35.43 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 22.46 per cent from ₹45.69 crore. This corresponds to a year-on-year *(YoY) growth of 0.62 per cent.
Net Profit
Net Profit stands at ₹27.51 crore, reflecting a quarter-on-quarter *(QoQ) increase of 82.91 per cent from ₹15.04 crore. This represents a 3.07 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Morepen Laboratories Ltd News
Morepen Laboratories Ltd Earnings
- YOY
- QOQ
Morepen Laboratories Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Morepen Laboratories Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Morepen Laboratories Ltd Financial Reports
Morepen Laboratories Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Morepen Labs. | 3.99% | 1.18% | 16.13% | -8.86% | -18.51% | -23.01% |
| Hikal | 0.20% | -1.08% | 4.01% | -7.38% | -21.15% | -42.19% |
| Novartis India | 20.00% | 20.70% | 24.45% | 21.26% | 6.28% | 18.33% |
| Bliss GVS Pharma | -1.48% | -3.54% | 33.44% | 31.67% | 40.41% | 65.43% |
| IOL Chemicals | -1.49% | -1.81% | 4.83% | -20.97% | -22.46% | 8.35% |
| Panacea Biotec | -0.83% | -5.95% | -1.84% | -2.30% | -15.36% | 5.58% |
| Indoco Remedies | -0.97% | -2.12% | -9.76% | -21.50% | -29.84% | -11.57% |
Company Info
Company Information
Chairman / Executive Director / M D / Promoter : Sushil Suri
WTD & Executive Director : Sanjay Suri
Independent Non Exe. Director : Praveen Kumar Dutt
Independent Non Exe. Director : Ranjit Khattar
Independent Non Exe. Director : Savita
Independent Non Exe. Director : Sharad Jain
Company Secretary : Vipul Kumar Srivastava